NDAINTRAVENOUSPOWDER
Approved
Jan 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMEND (fosaprepitant dimeglumine) is an intravenous NK1 receptor antagonist approved in 2008 for prevention of chemotherapy-induced nausea and vomiting (CINV). It is administered as a powder formulation and works by blocking substance P signaling in the chemoreceptor trigger zone. The drug is a small-molecule complement to oral aprepitant, offering an IV option for patients unable to take oral medications.
$0.062BPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Medicare spending (~$62K in 2023), indicating a mature, stable franchise with limited growth potential and likely smaller commercial teams focused on maintenance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Started Jun 2014
136 enrolled
NauseaVomitingGlioma
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Started Sep 2012
1,015 enrolled
Chemotherapy-Induced Nausea and Vomiting (CINV)
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
Started Oct 2011
111 enrolled
NauseaVomiting
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
Started Aug 2008
34 enrolled
Breakthrough Nausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific
Worked on EMEND at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.